19-02-2025, 19:05

Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer

Notified -
Globe Newswire19-02-2025, 19:05
9-09-2024, 22:45

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Globe Newswire9-09-2024, 22:45
27-08-2024, 14:05

Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Globe Newswire27-08-2024, 14:05